SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood
Highly accurate antibody tests for SARS-CoV-2 are needed for surveillance in low-prevalence populations. Here, the authors find seroprevalence of less than 1% in two San Francisco Bay Area populations at the beginning of April, and that seroreactivity is generally predictive of in vitro neutralising...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-09-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-18468-8 |
| id |
doaj-b4b0b2c17edb43c98ec84b755fb3600a |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Dianna L. Ng Gregory M. Goldgof Brian R. Shy Andrew G. Levine Joanna Balcerek Sagar P. Bapat John Prostko Mary Rodgers Kelly Coller Sandra Pearce Sergej Franz Li Du Mars Stone Satish K. Pillai Alicia Sotomayor-Gonzalez Venice Servellita Claudia Sanchez San Martin Andrea Granados Dustin R. Glasner Lucy M. Han Kent Truong Naomi Akagi David N. Nguyen Neil M. Neumann Daniel Qazi Elaine Hsu Wei Gu Yale A. Santos Brian Custer Valerie Green Phillip Williamson Nancy K. Hills Chuanyi M. Lu Jeffrey D. Whitman Susan L. Stramer Candace Wang Kevin Reyes Jill M. C. Hakim Kirk Sujishi Fariba Alazzeh Lori Pham Edward Thornborrow Ching-Ying Oon Steve Miller Theodore Kurtz Graham Simmons John Hackett Michael P. Busch Charles Y. Chiu |
| spellingShingle |
Dianna L. Ng Gregory M. Goldgof Brian R. Shy Andrew G. Levine Joanna Balcerek Sagar P. Bapat John Prostko Mary Rodgers Kelly Coller Sandra Pearce Sergej Franz Li Du Mars Stone Satish K. Pillai Alicia Sotomayor-Gonzalez Venice Servellita Claudia Sanchez San Martin Andrea Granados Dustin R. Glasner Lucy M. Han Kent Truong Naomi Akagi David N. Nguyen Neil M. Neumann Daniel Qazi Elaine Hsu Wei Gu Yale A. Santos Brian Custer Valerie Green Phillip Williamson Nancy K. Hills Chuanyi M. Lu Jeffrey D. Whitman Susan L. Stramer Candace Wang Kevin Reyes Jill M. C. Hakim Kirk Sujishi Fariba Alazzeh Lori Pham Edward Thornborrow Ching-Ying Oon Steve Miller Theodore Kurtz Graham Simmons John Hackett Michael P. Busch Charles Y. Chiu SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood Nature Communications |
| author_facet |
Dianna L. Ng Gregory M. Goldgof Brian R. Shy Andrew G. Levine Joanna Balcerek Sagar P. Bapat John Prostko Mary Rodgers Kelly Coller Sandra Pearce Sergej Franz Li Du Mars Stone Satish K. Pillai Alicia Sotomayor-Gonzalez Venice Servellita Claudia Sanchez San Martin Andrea Granados Dustin R. Glasner Lucy M. Han Kent Truong Naomi Akagi David N. Nguyen Neil M. Neumann Daniel Qazi Elaine Hsu Wei Gu Yale A. Santos Brian Custer Valerie Green Phillip Williamson Nancy K. Hills Chuanyi M. Lu Jeffrey D. Whitman Susan L. Stramer Candace Wang Kevin Reyes Jill M. C. Hakim Kirk Sujishi Fariba Alazzeh Lori Pham Edward Thornborrow Ching-Ying Oon Steve Miller Theodore Kurtz Graham Simmons John Hackett Michael P. Busch Charles Y. Chiu |
| author_sort |
Dianna L. Ng |
| title |
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood |
| title_short |
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood |
| title_full |
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood |
| title_fullStr |
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood |
| title_full_unstemmed |
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood |
| title_sort |
sars-cov-2 seroprevalence and neutralizing activity in donor and patient blood |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2020-09-01 |
| description |
Highly accurate antibody tests for SARS-CoV-2 are needed for surveillance in low-prevalence populations. Here, the authors find seroprevalence of less than 1% in two San Francisco Bay Area populations at the beginning of April, and that seroreactivity is generally predictive of in vitro neutralising activity. |
| url |
https://doi.org/10.1038/s41467-020-18468-8 |
| work_keys_str_mv |
AT diannalng sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT gregorymgoldgof sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT brianrshy sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT andrewglevine sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT joannabalcerek sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT sagarpbapat sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT johnprostko sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT maryrodgers sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT kellycoller sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT sandrapearce sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT sergejfranz sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT lidu sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT marsstone sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT satishkpillai sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT aliciasotomayorgonzalez sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT veniceservellita sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT claudiasanchezsanmartin sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT andreagranados sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT dustinrglasner sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT lucymhan sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT kenttruong sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT naomiakagi sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT davidnnguyen sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT neilmneumann sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT danielqazi sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT elainehsu sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT weigu sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT yaleasantos sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT briancuster sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT valeriegreen sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT phillipwilliamson sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT nancykhills sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT chuanyimlu sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT jeffreydwhitman sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT susanlstramer sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT candacewang sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT kevinreyes sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT jillmchakim sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT kirksujishi sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT faribaalazzeh sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT loripham sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT edwardthornborrow sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT chingyingoon sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT stevemiller sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT theodorekurtz sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT grahamsimmons sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT johnhackett sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT michaelpbusch sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood AT charlesychiu sarscov2seroprevalenceandneutralizingactivityindonorandpatientblood |
| _version_ |
1717375444425113600 |
| spelling |
doaj-b4b0b2c17edb43c98ec84b755fb3600a2021-09-19T11:51:34ZengNature Publishing GroupNature Communications2041-17232020-09-011111710.1038/s41467-020-18468-8SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient bloodDianna L. Ng0Gregory M. Goldgof1Brian R. Shy2Andrew G. Levine3Joanna Balcerek4Sagar P. Bapat5John Prostko6Mary Rodgers7Kelly Coller8Sandra Pearce9Sergej Franz10Li Du11Mars Stone12Satish K. Pillai13Alicia Sotomayor-Gonzalez14Venice Servellita15Claudia Sanchez San Martin16Andrea Granados17Dustin R. Glasner18Lucy M. Han19Kent Truong20Naomi Akagi21David N. Nguyen22Neil M. Neumann23Daniel Qazi24Elaine Hsu25Wei Gu26Yale A. Santos27Brian Custer28Valerie Green29Phillip Williamson30Nancy K. Hills31Chuanyi M. Lu32Jeffrey D. Whitman33Susan L. Stramer34Candace Wang35Kevin Reyes36Jill M. C. Hakim37Kirk Sujishi38Fariba Alazzeh39Lori Pham40Edward Thornborrow41Ching-Ying Oon42Steve Miller43Theodore Kurtz44Graham Simmons45John Hackett46Michael P. Busch47Charles Y. Chiu48Department of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoApplied Research and Technology, Abbott DiagnosticsApplied Research and Technology, Abbott DiagnosticsApplied Research and Technology, Abbott DiagnosticsApplied Research and Technology, Abbott DiagnosticsVitalant Research InstituteVitalant Research InstituteDepartment of Laboratory Medicine, University of California, San FranciscoVitalant Research InstituteDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Medicine, Division of Infectious Diseases, University of California, San FranciscoDepartment of Pathology, University of California, San FranciscoDepartment of Pathology, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoVitalant Research InstituteCreative Testing SolutionsCreative Testing SolutionsDepartment of Neurology, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoAmerican Red CrossDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Medicine at ZSFG, The Division of HIV, ID & Global MedicineDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoApplied Research and Technology, Abbott DiagnosticsDepartment of Laboratory Medicine, University of California, San FranciscoDepartment of Laboratory Medicine, University of California, San FranciscoHighly accurate antibody tests for SARS-CoV-2 are needed for surveillance in low-prevalence populations. Here, the authors find seroprevalence of less than 1% in two San Francisco Bay Area populations at the beginning of April, and that seroreactivity is generally predictive of in vitro neutralising activity.https://doi.org/10.1038/s41467-020-18468-8 |